TY - JOUR T1 - Change in biomarkers of type-2 inflammation following severe exacerbations of asthma JF - Thorax JO - Thorax SP - 95 LP - 98 DO - 10.1136/thoraxjnl-2018-211657 VL - 74 IS - 1 AU - Ruth Semprini AU - Nick Shortt AU - Stefan Ebmeier AU - Alex Semprini AU - Rachel Varughese AU - Cecile T J Holweg AU - John G Matthews AU - James Fingleton AU - Mark Weatherall AU - Richard Beasley AU - Irene Braithwaite Y1 - 2019/01/01 UR - http://thorax.bmj.com/content/74/1/95.abstract N2 - We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×109/L, p<0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p<0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p<0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma.Trial registration number Post-results; The Australia New Zealand Trial Registry, >ACTRN12614000443695. ER -